Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 known ✓ | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 known ✓ | P35228 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 6/20 | 0.32 |
| ▸ | ACLY | P53396 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 4/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8173539 | 0.94 | LMNA (0.35) | FFAR3LCKFYNTSHRALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4872786 | 0.91 | TSHR (0.37) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL19552090 | 0.91 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL19552101 | 0.91 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL4163974 | 0.91 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL3634014 | 0.91 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL1525100 | 0.91 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL60574 | 0.91 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL9632138 | 0.91 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY | |
| Trifluoroacetic Acid SCHEMBL4809831 | 0.91 | ALDH1A1 (0.41) | TSHRALDH1A1TP53FAAHACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927230-B2 | C-terminal modification of polypeptides | EUCODIS BIOSCIENCE GMBH (AT) | 2015-01-06 | — | — | US | disclosed |
| US-20130177940-A1 | C-TERMINAL MODIFICATION OF POLYPEPTIDES | Bordusa, Frank (DE) | 2013-07-11 | — | — | US | disclosed |
| EP-1778839-B1 | C-TERMINAL MODIFICATION OF POLYPEPTIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20080064079-A1 | Mutant trypsin; protein engineering and sequencing | ROCHE DIAGNOSTICS GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| US-7335644-B2 | Anti-hypertensive molecules and process for preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-02-26 | — | — | US | disclosed |
| EP-1778839-A1 | C-TERMINAL MODIFICATION OF POLYPEPTIDES | Roche Diagniostics GMBH (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015879-A1 | C-TERMINAL MODIFICATION OF POLYPEPTIDES | ROCHE DIAGNIOSTICS GMBH (DE) | 2006-02-16 | — | — | WO | disclosed |
| US-20020183249-A1 | Method of identifying inhibitors of CDC25 | TAYLOR NEIL R (AU) | 2002-12-05 | — | — | US | disclosed |
| WO-2002070680-A1 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-12 | — | — | WO | disclosed |
| EP-1226237-A2 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027077-A2 | HYDROXYSULFONYLALKYLENE-, PHOSPHONOALKYLENE- OR DIFLUORO(PHOSPHONONON)METHYL- SUBSTITUTED BENZENE, OR BENZOFURAN DERIVATIVES AS NON-PEPTIDIC CDC25 INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001016300-A2 | METHOD OF IDENTIFYING INHIBITORS OF CDC25 | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183249-A1 | Method of identifying inhibitors of CDC25 | CDC25C, CDC25A, CDC25B | NOS1 4592/4885NOS2 4641/4885FFAR3 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.